Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amviacin AP
- Development stage
- Unknown
- Lead developer
- Insmed
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amviacin AP is a commercial generic fixed-dose combination (FDC) medication containing aceclofenac and paracetamol (acetaminophen), marketed by AMVIO (Amvia Biotech). Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class that acts as a preferential inhibitor of the cyclooxygenase-2 (COX-2) enzyme, thereby reducing the synthesis of inflammatory prostaglandins. Paracetamol is a widely used analgesic and antipyretic agent that is thought to act primarily in the central nervous system by inhibiting prostaglandin synthesis. This combination is indicated for the symptomatic relief of pain and inflammation associated with musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It is typically administered orally in tablet form and is part of a broader portfolio of commercial generic formulations produced by the company.
- Brand names
- Amviacin AP
- Other names
- Aceclofenac + ParacetamolAceclofenac/ParacetamolAceclofenac/Acetaminophen
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Amviacin AP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amviacin AP.